1) Circulating specific HBcAg complex
HBcAg循环免疫复合物
2) Circulating Immune Complexes
循环免疫复合物
1.
The relationship between cholesterol level in circulating immune complexes and ischemic cardiocerebral diseases;
血清循环免疫复合物中胆固醇含量与缺血性心脑血管疾病关系的研究
2.
Objective To look for a new full-automatic instrumental method for Circulating Immune Complexes (CIC) de- termination,to replace the tedious handicraft labor of traditional method and gain more accurate results.
目的:寻求一种全自动仪测循环免疫复合物(CIC)的新方法,以取代传统方法繁琐的手工劳动和略显粗糙的定量结果。
3.
Objective To probe the relationship of serumal HBVM with HBsAg-special/nonspecial-circulating immune complexes.
目的 探讨乙型肝炎患者血清 HBV抗原抗体标志物和 HBs Ag特异及非特异性循环免疫复合物间的关系。
3) Circular immune complex
循环免疫复合物
1.
Objective: to establish a sensitive and special method of double mono-cloned antibody for examining the circular immune complex (CIC) in blood, and to further probe the relation between CIC of chlamydia pneumoniae (Cpn) and the coronary heart disease.
目的：建立一种敏感而且特异的双抗体夹心法检测血液中的循环免疫复合物(CIC)，并讨论血液中肺炎衣原体(Cpn)CIC与冠心病的关系。
4) immune complexes
循环免疫复合物
1.
Effects of iow-density lipoprotein-containing immune complexes on matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in U937 cells;
低密度脂蛋白循环免疫复合物对U937细胞基质金属蛋白酶-1及其抑制物的作用
5) circulation immune complex
循环免疫复合物
1.
Establishment of the detection method for drug-derived circulation immune complex
药源性循环免疫复合物检测方法的建立
6) CIC
循环免疫复合物
1.
Changes of CR1 on erythrocytes and CIC in patients with hepatitis B;
肝炎患者红细胞免疫分子CR1定量与循环免疫复合物的变化
2.
Methods Using the model of immune function in low level induced by cyclophosphamide injection,effects of Ganneng dripping pills on phagocytosis of macrophage and levels of CIC in mice,were observed.
方法通过腹腔注射环磷酰胺造成小鼠免疫功能低下,以腹腔巨噬细胞的吞噬功能、循环免疫复合物水平为观察指标,观察肝能滴丸对环磷酰胺处理的小鼠免疫功能低下的影响。
3.
Objective To explore existing state and its pathology meanings of the two component circulating immune complexes of IgG specific activing complement(IgG/C\-3-TCIC) in patients with Graves disease(GD).
目的 探讨甲状腺机能亢进 (Gravesdisease,GD)患者IgG特异性激活补体类循环免疫复合物 (IgG/C3 -TCIC)的存在状况及其病理生理意义。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条